Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593276 | 0.89 | THRB (0.56) | POLBCYP2C9ALDH1A1MAPTKMT2A | |
| SCHEMBL5012624 | 0.86 | POLB (0.70) | POLBCYP2C9NR3C2MAPTNAAA | |
| SCHEMBL5010850 | 0.85 | POLB (0.58) | POLBCYP2C9NR3C2MAPTNAAA | |
| SCHEMBL18581314 | 0.84 | POLB (0.56) | POLBNR3C2ALDH1A1MAPTNAAA | |
| SCHEMBL4890179 | 0.84 | CYP2C9 (0.50) | POLBCYP2C9NR3C2ALDH1A1MAPT | |
| SCHEMBL17276259 | 0.81 | CYP2C9 (0.55) | POLBCYP2C9ALDH1A1MAPTKMT2A | |
| SCHEMBL21382774 | 0.80 | CYP2C9 (0.65) | POLBCYP2C9ALDH1A1KMT2ANPC1 | |
| SCHEMBL18581808 | 0.80 | CYP2C9 (0.53) | POLBCYP2C9ALDH1A1MAPTTHRB | |
| SCHEMBL2881942 | 0.80 | CYP2C9 (0.53) | CYP2C9ALDH1A1MAPTNOTUMTHRB | |
| SCHEMBL18581215 | 0.79 | CYP2C9 (0.54) | CYP2C9ALDH1A1MAPTKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180354919-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2018-12-13 | — | — | US | disclosed |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2017-03-09 | — | — | US | disclosed |
| WO-2017040963-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040963-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066729-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | POLB 2819/4885CYP2C9 874/4885NR3C2 580/4885 |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | POLB 2819/4885CYP2C9 874/4885NR3C2 580/4885 |
| US-20210139439-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | POLB 2819/4885CYP2C9 874/4885NR3C2 580/4885 |
| US-20180354919-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | POLB 2819/4885CYP2C9 874/4885NR3C2 580/4885 |
| US-10370343-B2 | [6,6] Fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | POLB 2819/4885CYP2C9 874/4885NR3C2 580/4885 |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | POLB 2819/4885CYP2C9 874/4885NR3C2 580/4885 |
| US-20190308946-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | POLB 2819/4885CYP2C9 874/4885NR3C2 580/4885 |
| US-10829460-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC1, HDAC2 | POLB 2117/4885CYP2C9 2641/4885NR3C2 347/4885 |
| US-10029995-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | POLB 2819/4885CYP2C9 874/4885NR3C2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.